Special Issue

Dendritic Cells (DCs) and Cancer Immunotherapy: 2nd Edition

Message from the Guest Editor

Several obstacles hinder the success of Dendritic cell (DC) vaccines, including tumor-mediated immunosuppression and the functional limitations of DCs differentiated in vitro. To address these challenges, researchers are exploring alternatives such as DC-derived exosomes (DCexos), which have gained attention as potential cell-free therapeutic vaccines. Additionally, in vivo DC-targeted vaccines and the use of naturally circulating blood DCs offer promising strategies compared to in vitro cultured DCs. Nonetheless, there are significant gaps in our understanding of the fundamental biology of these approaches, such as how DCexos and different DC subsets prime T cells, which impedes their translation into clinical applications. Furthermore, an enhanced understanding of how DCs interact with other immune cells, such as other DCs, B cells, and NK cells, is crucial in fully realizing the potential of DC-based vaccines. This Special Issue welcomes new research articles and reviews that explore all aspects of dendritic cells and their contributions to vaccine development and cancer immunotherapy.

Guest Editor

Dr. Aimin Jiang

1. Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health System, Detroit, MI, USA
2. Immunology Research Program, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, MI, USA

Deadline for manuscript submissions

31 July 2026

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/252852

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI